688621 阳光诺和
已收盘 07-10 15:00:01
资讯
新帖
简况
阳光诺和：合同生效后相关研发费用由客户承担
证券之星 · 07-09 15:37
阳光诺和：合同生效后相关研发费用由客户承担
阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作
证券之星 · 07-09 15:37
阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作
阳光诺和：募集资金用于小核酸实验室和产能建设
证券之星 · 07-09 15:37
阳光诺和：募集资金用于小核酸实验室和产能建设
阳光诺和：公司多肽合成以化学合成技术为主
证券之星 · 07-09 15:37
阳光诺和：公司多肽合成以化学合成技术为主
阳光诺和：仿制药药学研究服务收入3.39亿元，同比下降39.41%
证券之星 · 07-09 15:37
阳光诺和：仿制药药学研究服务收入3.39亿元，同比下降39.41%
阳光诺和：本公司给予高度重视，并致力于追求高质量的发展战略
证券之星 · 07-09 15:36
阳光诺和：本公司给予高度重视，并致力于追求高质量的发展战略
7月7日阳光诺和跌9.29%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 07-07
7月7日阳光诺和跌9.29%，融通健康产业灵活配置混合A/B基金重仓该股
每周股票复盘：阳光诺和（688621）拟募2.4亿投核酸药研发
证券之星 · 07-05
每周股票复盘：阳光诺和（688621）拟募2.4亿投核酸药研发
阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票预案，7月3日股价上涨0.56%
证券之星 · 07-03
阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票预案，7月3日股价上涨0.56%
阳光诺和(688621.SH)拟募资不超2.4亿元 用于核酸药物发现与中试实验平台研发建设项目等
智通财经 · 07-03
阳光诺和(688621.SH)拟募资不超2.4亿元 用于核酸药物发现与中试实验平台研发建设项目等
股市必读：阳光诺和（688621）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
证券之星 · 07-03
股市必读：阳光诺和（688621）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
每周股票复盘：阳光诺和（688621）每10股派1.87元现金红利
证券之星 · 06-28
每周股票复盘：阳光诺和（688621）每10股派1.87元现金红利
阳光诺和（688621）披露2025年年度权益分派实施公告，6月22日股价下跌2.14%
证券之星 · 06-22
阳光诺和（688621）披露2025年年度权益分派实施公告，6月22日股价下跌2.14%
6月8日阳光诺和跌5.05%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 06-08
6月8日阳光诺和跌5.05%，融通健康产业灵活配置混合A/B基金重仓该股
阳光诺和（688621）披露参与设立杭州启真智康股权投资合伙企业公告，6月1日股价下跌2.78%
证券之星 · 06-01
阳光诺和（688621）披露参与设立杭州启真智康股权投资合伙企业公告，6月1日股价下跌2.78%
每周股票复盘：阳光诺和（688621）STC008项目权益转让终止
证券之星 · 05-31
每周股票复盘：阳光诺和（688621）STC008项目权益转让终止
阳光诺和(688621.SH)拟500万元认购启真智康基金份额
智通财经 · 05-29
阳光诺和(688621.SH)拟500万元认购启真智康基金份额
每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理
证券之星 · 05-24
每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理
阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理
智通财经 · 05-22
阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理
阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%
证券之星 · 05-15
阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%
加载更多
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":51.61,"timestamp":1783666801000,"preClose":49.25,"halted":0,"volume":3340806,"delay":0,"changeRate":0.0479,"floatShares":112000000,"shares":112000000,"eps":1.7404,"marketStatus":"已收盘","change":2.36,"latestTime":"07-10 15:00:01","open":49.47,"high":53.23,"low":48.09,"amount":173000000,"amplitude":0.1044,"askPrice":51.61,"askSize":33,"bidPrice":51.56,"bidSize":18,"shortable":0,"etf":0,"ttmEps":1.7404,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":5,"adr":0,"adjPreClose":49.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783647000000,1783654200000],[1783659600000,1783666800000]],"highLimit":54.18,"lowLimit":44.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"isCdr":false,"pbRate":4.61,"roa":"--","peRate":29.654103,"roe":"1.67%","epsLYR":1.86,"committee":-0.530612,"marketValue":5780000000,"turnoverRate":0.0298,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-07-13。","afterMarket":{"amount":0,"volume":0,"close":51.61,"buyVolume":0,"sellVolume":500,"time":1783668837746,"indexStatus":"已收盘 07-10 15:30:00","preClose":49.25},"floatMarketCap":5780000000},"requestUrl":"/m/hq/s/688621","defaultTab":"news","newsList":[{"id":"2650944171","title":"阳光诺和：合同生效后相关研发费用由客户承担","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944171?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582631,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司自研项目BD后研发费用是否由客户承担，如STC007等项目研发费用今后不会在报表中体现？阳光诺和回复：合同生效后，后续临床试验、注册申报及商业化阶段的主要研发工作由客户负责组织实施，相关研发费用由客户承担。感谢您对公司的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944197","title":"阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944197","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944197?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582626,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司进行中的BD有？，在谈中的创新药BD有？有什么创新药成果？阳光诺和回复：公司正基于管线进展有序推进国内外合作洽谈相关工作，若有达成实质性合作，将根据《上海证券交易所股票上市规则》等相关要求及时披露。后续公司将持续通过对外授权、联合开发等多元化模式，最大化管线价值，具体合作动态请以公司公告为准。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944144","title":"阳光诺和：募集资金用于小核酸实验室和产能建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944144?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582625,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：2025 年公司新签订单突破 20 亿，现有实验室产能能否匹配未来 2 年订单交付？是否启动新研发基地扩建、新增临床分析实验室规划？公司持续关注产能建设与订单交付、自主研发的匹配。近期，公司公告以简易程序向特定对象发行股票预案，募集资金用于小核酸实验室和产能建设。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944108","title":"阳光诺和：公司多肽合成以化学合成技术为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944108?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582623,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：多肽原料药合成生物学酶法工艺是否完成内部验证？未来能否对外提供合成生物中间体研发服务，该技术能否大幅降低公司多肽类项目研发成本、提升整体毛利率？有无相关产学研合作落地？阳光诺和回复：尊敬的投资者，您好！公司多肽合成以化学合成技术为主。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944119","title":"阳光诺和：仿制药药学研究服务收入3.39亿元，同比下降39.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944119","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944119?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582622,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：仿制药一致性评价业务持续受集采降价影响，公司持续收缩低毛利仿制服务，2026 年仿制类订单收入占比是否会进一步下滑？从2025年经营数据来看，公司仿制药药学研究服务收入3.39亿元，同比下降39.41%；与此同时，新增创新药、改良型新药研发服务板块，实现收入2.48亿元，毛利率达96.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650126944","title":"阳光诺和：本公司给予高度重视，并致力于追求高质量的发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2650126944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650126944?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:36","pubTimestamp":1783582618,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和07月09日在投资者关系平台上答复投资者关心的问题。对于您对本公司的关注，我们表示衷心的感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649543988","title":"7月7日阳光诺和跌9.29%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649543988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649543988?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:32","pubTimestamp":1783413134,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日阳光诺和跌9.29%，收盘报51.15元，换手率3.04%，成交量3.4万手，成交额1.8亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700027489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649692315","title":"每周股票复盘：阳光诺和（688621）拟募2.4亿投核酸药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692315","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649692315?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:30","pubTimestamp":1783193430,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，阳光诺和报收于56.05元，较上周的50.58元上涨10.81%。本周，阳光诺和7月3日盘中最高价报57.98元。本周关注点来自公司公告汇总：阳光诺和拟以简易程序向特定对象发行股票，募集资金总额不超过24,000.00万元，用于核酸药物研发平台建设及补充流动资金。公司2025年实现营业收入12.22亿元，同比增长13.33%，新增创新药及改良型新药研发服务、知识产权授权等业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648039661","title":"阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票预案，7月3日股价上涨0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648039661","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648039661?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:43","pubTimestamp":1783089796,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，阳光诺和报收于56.05元，较前一交易日上涨0.56%，最新总市值为62.78亿元。近日，北京阳光诺和药物研究股份有限公司披露《2026年度以简易程序向特定对象发行股票预案》。公告显示，公司拟以简易程序向特定对象发行股票，募集资金总额不超过24,000.00万元，用于核酸药物发现与中试实验平台研发建设项目及补充流动资金。本次发行股票数量不超过发行前总股本的30%，发行对象不超过35名特定投资者，限售期为六个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300046006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648666941","title":"阳光诺和(688621.SH)拟募资不超2.4亿元 用于核酸药物发现与中试实验平台研发建设项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2648666941","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648666941?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:40","pubTimestamp":1783082450,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)披露2026年度以简易程序向特定对象发行股票预案，拟募集资金总额为不超过2.4亿元(含)，发行的募集资金在扣除发行费用后将用于：核酸药物发现与中试实验平台研发建设项目、补充流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648808926","title":"股市必读：阳光诺和（688621）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648808926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648808926?lang=zh_cn&edition=full","pubTime":"2026-07-03 03:09","pubTimestamp":1783019351,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，阳光诺和报收于55.74元，下跌1.14%，换手率2.12%，成交量2.38万手，成交额1.34亿元。公司公告汇总：阳光诺和就2025年年报收到上交所问询函，回复涉及主营业务、自主立项项目、关联交易等事项，并披露2025年营业收入12.22亿元，同比增长13.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300002178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646155173","title":"每周股票复盘：阳光诺和（688621）每10股派1.87元现金红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2646155173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646155173?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:14","pubTimestamp":1782587650,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，阳光诺和报收于50.58元，较上周的52.4元下跌3.47%。本周，阳光诺和6月25日盘中最高价报54.49元。公司公告汇总北京阳光诺和药物研究股份有限公司2025年年度权益分派实施公告：本次利润分配方案经2026年5月15日召开的2025年年度股东会审议通过。北京市天元律师事务所就北京阳光诺和药物研究股份有限公司2025年度利润分配方案涉及的差异化分红事项出具专项法律意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645735730","title":"阳光诺和（688621）披露2025年年度权益分派实施公告，6月22日股价下跌2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645735730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645735730?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:28","pubTimestamp":1782138498,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，阳光诺和报收于51.28元，较前一交易日下跌2.14%，最新总市值为57.43亿元。该股当日开盘52.39元，最高52.6元，最低49.76元，成交额达1.05亿元，换手率为1.85%。近日，阳光诺和发布《2025年年度权益分派实施公告》。公告显示，本次利润分配方案经2026年5月15日召开的2025年年度股东会审议通过。股权登记日为2026年6月26日，除权（息）日为2026年6月29日，现金红利发放日为2026年6月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107195","title":"6月8日阳光诺和跌5.05%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107195?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:47","pubTimestamp":1780908434,"startTime":"0","endTime":"0","summary":"证券之星消息，6月8日阳光诺和跌5.05%创60日新低，收盘报47.96元，换手率1.37%，成交量1.54万手，成交额7453.61万元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958668","title":"阳光诺和（688621）披露参与设立杭州启真智康股权投资合伙企业公告，6月1日股价下跌2.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958668","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640958668?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:02","pubTimestamp":1780308125,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，阳光诺和报收于52.5元，较前一交易日下跌2.78%，最新总市值为58.8亿元。近日，北京阳光诺和药物研究股份有限公司发布《关于参与设立杭州启真智康股权投资合伙企业的公告》。公告显示，公司拟以自有资金认缴出资500万元，参与设立杭州启真智康股权投资合伙企业，占基金总认缴出资额的18.87%，担任有限合伙人。该基金专项投资于杭州翊圣生物科技有限公司，聚焦慢性炎症与重大慢病新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100028487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604987","title":"每周股票复盘：阳光诺和（688621）STC008项目权益转让终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604987?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:20","pubTimestamp":1780168821,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，阳光诺和报收于54.0元，较上周的56.25元下跌4.0%。本周，阳光诺和5月25日盘中最高价报58.77元。公司公告汇总关于STC008注射液签署《技术开发合同补充协议》的进展公告北京阳光诺和药物研究股份有限公司与星浩控股、亚太药业于2026年4月签订STC008注射液《技术开发合同补充协议》，约定星浩控股将STC008项目权益转让给亚太药业。STC008项目权益仍由星浩控股持有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639362569","title":"阳光诺和(688621.SH)拟500万元认购启真智康基金份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2639362569","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639362569?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:25","pubTimestamp":1780046736,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，公司于近日与北京浙商华盈创业投资管理有限公司及其他合伙人签署合伙协议，以自有资金500万元认购杭州启真智康股权投资合伙企业(有限合伙)(简称“启真智康基金”)份额，担任有限合伙人，占合伙企业总认缴出资额的18.87%，由于启真智康基金尚处于募集阶段，公司持有的份额比例以最终募集完成情况为准。启真智康基金专项投资于杭州翊圣生物科技有限公司(简称“翊圣生物”)，翊圣生物聚焦慢性炎症与重大慢病新药研发，从慢性炎症的角度为相关疾病发现防治新靶点和新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637376472","title":"每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637376472","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637376472?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:16","pubTimestamp":1779570975,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，阳光诺和报收于56.25元，较上周的56.18元上涨0.12%。本周，阳光诺和5月21日盘中最高价报59.3元。本周关注点公司公告汇总：STC009注射液临床试验申请获国家药监局受理公司公告汇总自愿披露关于STC009注射液临床试验申请获得受理的公告北京阳光诺和药物研究股份有限公司全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局签发的《受理通知书》，其在研项目STC009注射液的临床试验申请已获受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637012391","title":"阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637012391","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637012391?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:17","pubTimestamp":1779437831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和 发布公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目STC009注射液的临床试验申请获得受理。本次递交的STC009注射液为1类创新药，拟申报适应症为继发性甲状旁腺功能亢进症。STC009注射液是诺和晟泰依托公司独有的iCVETide多肽新药发现平台开发的钙离子敏感受体多肽激动剂，药物分子发现的相关研究成果已发表于国际顶级期刊Journalof Medicinal Chemistry。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358180","title":"阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635358180?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:52","pubTimestamp":1778856734,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，阳光诺和报收于56.18元，较前一交易日下跌1.13%，最新总市值为62.92亿元。该股当日开盘56.81元，最高57.49元，最低55.8元，成交额达1.04亿元，换手率为1.64%。近日，阳光诺和披露《2025年年度股东会决议公告》。本次会议无被否决议案，表决程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783807903541,"stockEarnings":[{"period":"1week","weight":-0.0792},{"period":"1month","weight":0.0355},{"period":"3month","weight":-0.2211},{"period":"6month","weight":-0.3331},{"period":"1year","weight":0.0176},{"period":"ytd","weight":-0.1666}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7988人(较上一季度增加11.58%)","perCapita":"14021股","listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","registeredCapital":"11200万元","survey":" 北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。","listedPrice":26.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}